A Unique Approach to Dog Cancer Treatment
Imagine going to extraordinary lengths for your beloved pet. That’s exactly what Paul Conyngham, an Australian tech entrepreneur, did when his 8-year-old dog, Rosie, was diagnosed with a severe form of mast cell cancer. Faced with a grim prognosis and draining funds on treatments that seemed ineffective, Conyngham turned to an unexpected ally: ChatGPT.
After extensive chemotherapy and surgeries that yielded little hope, he sought the chatbot’s help to identify a possible cure. It was there that immunotherapy emerged as a suggestion. Conyngham then contacted the UNSW Ramaciotti Genomics Center to sequence Rosie’s DNA.
Associate Professor Martin Smith from UNSW commented on the unusual inquiry they received, stating, “We often get strange questions and this one came from an individual looking to sequence their dog. DNA sequencing can help profile tumors and pin down mutations that may be causing illness.” Conyngham, investing around $3,000 into the sequencing, utilized his 17 years of expertise in machine learning and data analytics to sift through the tumor’s genetic data.
Through this analysis, he designed a blueprint for an mRNA vaccine by leveraging data pipelines to find mutated proteins within the tumors and matching them with drugs that could potentially combat cancer.
Conyngham continued his dialogue with Smith and the UNSW team, seeking their expertise in synthesizing a therapeutic compound for Rosie. While the process has faced challenges—like a refusal to use a certain immunotherapy drug from a pharmaceutical company—the team eventually created the world’s first personalized mRNA cancer vaccine, based on a part of Conyngham’s coding work, with guidance from Pall Thordarson, director of the UNSW RNA Institute.
Still, they encountered a significant obstacle: securing ethical approval to conduct a drug trial on Rosie. Conyngham remarked, “The red tape was actually more demanding than developing the vaccine. It took me three months and countless hours just to compile a 100-page document.” Luckily, Rachel Aravena, a professor of canine immunotherapy at the University of Queensland, lent her assistance, facilitating the experimental treatment.
Once the custom vaccine was ready, it was sent to her lab, about a 10-hour drive from Conyngham’s home. After the journey, Rosie received her first vaccination in December, followed by a booster last month and another booster expected this week.
The results have been remarkable. Even though the cancer had advanced, the previously tennis ball-sized tumor on Rosie’s foot has shrunk to half its size. She’s also showing signs of improved health—her coat is shinier, and her mood appears much brighter.
While Conyngham is currently working on a second vaccine for another tumor that hasn’t reacted to treatment, he is pleased with the substantial improvements in Rosie’s health and quality of life. “While we aren’t under any illusions that this is a complete cure, we believe it has greatly enhanced her time with us,” he said.
Smith remains optimistic about the implications of this research for human cancer treatment, posing the thought, “If dogs can benefit from this, why aren’t we extending this to all humans battling cancer? It brings hope to many people, and we are eager to advance in this area.”
